2024-07-30 09:10:33,960 - INFO - Number of trials found: 9
2024-07-30 09:10:33,961 - INFO - NCT IDs: ['NCT05325866', 'NCT05846789', 'NCT03821935', 'NCT04225117', 'NCT05194072', 'NCT04849364', 'NCT05902988', 'NCT05812807', 'NCT05633654']
2024-07-30 09:10:33,961 - INFO - Brief Titles: ['A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression', 'Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers', 'Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors', 'A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)', 'A Study of SGN-B7H4V in Advanced Solid Tumors', 'Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer', 'A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer', 'Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab', "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)"]
